Bristol-Myers Squibb Company stock price
Today's NYSE:BMY chart, history & news
Price:
63.81
USD
Change:
+0.23 (0.36%)
Key stats
| Price open | 63.75 |
|---|---|
| Previous close | 63.58 |
| Market cap | 142.55B |
| Volume | 6.47M |
| Day high | 63.96 |
| Day low | 63.58 |
| Year high | 66.64 |
| Year low | 52.43 |
| Year to date change | 4.03% |
| P/E ratio | -15.99 |
Company Profile
Fundamentals
Insider Information
News
About Bristol-Myers Squibb Company
Established in 1887 by William McLaren Bristol and John Ripley Myers, Bristol-Myers Squibb Company is a pharmaceutical company. Headquartered in New York, the company specializes in the development, manufacturing, licensing, and distribution of a wide range of pharmaceutical products.
The company’s pipeline of drugs includes novel treatments for oncology, immunoscience as well as cardiovascular and fibrotic illnesses. It’s lead products is Opdivo, a novel treatment for anti-cancer indications. It also sales Eliquis an oral inhibitor for stroke prevention as well as Orencia for patients with prostate-specific antigen.
Bristol-Myers Squibb Company has grown to become a juggernaut in the pharmaceutical space through acquisitions. Its biggest acquisition to date is that of Celgene in a deal valued at $74 billion. The acquisition should strengthen the company’s pipeline for cancer drugs and shrug of the effects of declining sales for lead product Opdivo.
Bristol-Myers Squibb Company has its stock listed on the New York Stock Exchange and is a component of the S&P 500 and S&P 100.
Company information
Company name
Bristol-Myers Squibb Company
Exchange
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Employees
30,000
CEO
Giovanni Caforio
Address
430 E 29th St Fl 14, New York, New York, 10016-8367
Country
United States
Contact information
12125464000
Website
https://www.bms.com/
Latest Bristol-Myers Squibb Company news
Bristol-Myers Squibb Company earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | |
|---|---|---|---|
| Actual EPS | 1.63 | 1.63 | 1.72 |
| Consensus EPS | 1.49457 | 1.48 | 1.49 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 14 | 12 | 11 |
| EPS Surprise Dollar | 0.13542902469635 | 0.15 | 0.23 |
| EPS Report Date | 05-11-2020 | 06-08-2020 | 07-05-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 31-03-2020 |
| Year Ago | 1.17 | 1.18 | 1.1 |
| Year Ago % Change | 39.316244018776% | 38.14% | 56.36% |
Bristol-Myers Squibb Company earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | 1.22 | 1.17 | 1.18 |
| Consensus EPS | 0.88 | 1.07 | 1.07 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 4 | 10 | 10 |
| EPS Surprise Dollar | 0.34 | 0.1 | 0.11 |
| EPS Report Date | 06-02-2020 | 31-10-2019 | 25-07-2019 |
| Fiscal End Date | 31-12-2019 | 30-09-2019 | 30-06-2019 |
| Year Ago | 0.94 | 1.09 | 1.01 |
| Year Ago % Change | 29.79% | 7.34% | 16.83% |
Bristol-Myers Squibb Company income statements (2020) (USD)
| August 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Total Revenue | 10.13B | 10.13B | 10.78B |
| Cost of Revenue | 2.70B | 5.08B | 5.93B |
| Gross Profit | 7.43B | 5.05B | 4.85B |
| Research & Development | 2.52B | 2.48B | 2.32B |
| Selling General & Admin | 1.63B | 1.63B | 1.61B |
| Operating Expense | 9.24B | 9.19B | 9.85B |
| Operating Income | 891M | 0.94B | 0.93B |
| Other Income Expense Net | 361M | 688M | -1.23B |
| EBIT | 2.07B | 0.94B | 0.93B |
| Interest Income | 357M | 357M | 362M |
| Pretax Income | 1.63B | 1.63B | -304M |
| Income Tax | 1.71B | 1.71B | 462M |
| Minority Interest | 5M | 5M | 9M |
| Net Income | -85M | -85M | -775M |
| Net Income Basic | -85M | -85M | -775M |
Bristol-Myers Squibb Company income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 7.95B | 6.01B | 6.27B | 5.92B |
| Cost of Revenue | 3.53B | 1.79B | 1.87B | 1.83B |
| Gross Profit | 4.42B | 4.22B | 4.40B | 4.09B |
| Research & Development | 1.99B | 1.36B | 1.31B | 1.30B |
| Selling General & Admin | 1.73B | 1.06B | 1.08B | 1.01B |
| Operating Expense | 7.24B | 4.21B | 4.26B | 4.14B |
| Operating Income | 701M | 1.80B | 2.02B | 1.78B |
| Other Income Expense Net | -830M | -453M | -242M | 196M |
| EBIT | 701M | 1.80B | 2.02B | 1.78B |
| Interest Income | 279M | 209M | 123M | 45M |
| Pretax Income | -129M | 1.35B | 1.78B | 1.98B |
| Income Tax | 0.93B | -17M | 337M | 264M |
| Minority Interest | -4M | 13M | 7M | 5M |
| Net Income | -1.06B | 1.35B | 1.43B | 1.71B |
| Net Income Basic | -1.06B | 1.35B | 1.43B | 1.71B |
Bristol-Myers Squibb Company income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 5.97B | 5.69B | 5.70B | 5.19B |
| Cost of Revenue | 1.69B | 1.65B | 1.60B | 1.59B |
| Gross Profit | 4.29B | 4.04B | 4.11B | 3.60B |
| Research & Development | 1.36B | 1.26B | 2.42B | 1.23B |
| Selling General & Admin | 1.34B | 1.10B | 1.13B | 0.98B |
| Operating Expense | 4.38B | 4.01B | 5.15B | 3.80B |
| Operating Income | 1.59B | 1.68B | 559M | 1.39B |
| Other Income Expense Net | -43M | 490M | -42M | 386M |
| EBIT | 1.59B | 1.68B | 559M | 1.39B |
| Interest Income | 48M | 44M | 45M | 46M |
| Pretax Income | 1.55B | 2.17B | 517M | 1.78B |
| Income Tax | 357M | 255M | 135M | 284M |
| Minority Interest | -2M | 11M | 9M | 9M |
| Net Income | 1.19B | 1.90B | 373M | 1.49B |
| Net Income Basic | 1.19B | 1.90B | 373M | 1.49B |
Bristol-Myers Squibb Company income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 5.45B | 5.25B | 5.14B |
| Cost of Revenue | 1.48B | 1.56B | 1.39B |
| Gross Profit | 3.97B | 3.69B | 3.76B |
| Research & Development | 1.39B | 1.48B | 1.09B |
| Selling General & Admin | 1.30B | 1.15B | 1.17B |
| Operating Expense | 4.17B | 4.19B | 3.64B |
| Operating Income | 1.28B | 1.06B | 1.50B |
| Other Income Expense Net | -579M | 119M | -207M |
| EBIT | 1.28B | 1.06B | 1.50B |
| Interest Income | 51M | 48M | 52M |
| Pretax Income | 698M | 1.18B | 1.30B |
| Income Tax | 3.03B | 327M | 373M |
| Minority Interest | -1M | 11M | 6M |
| Net Income | -2.33B | 845M | 0.92B |
| Net Income Basic | -2.33B | 845M | 0.92B |
Bristol-Myers Squibb Company balance sheet (2020) (USD)
| August 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 21.66B | 20.02B | 15.82B |
| Receivables | 7.86B | 6.70B | 7.20B |
| Inventory | 2.38B | 2.38B | 2.84B |
| Current Assets | 34.34B | 34.34B | 31.85B |
| Other Current Assets | 2.45B | 1.29B | 1.41B |
| Short Term Investments | 2.45B | 1.86B | 2.51B |
| Long Term Investments | 93.73B | 5.20B | 2.96B |
| Property/Plant Equipment | 5.78B | 6.48B | 6.84B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 59.17B | 59.17B | 61.67B |
| Tangible Assets (Net) | -30.66B | -60.07B | -63.07B |
| Other Assets | 1.67B | 1.22B | 2.91B |
| Total Assets | 128.08B | 128.08B | 129.29B |
| Accounts Payable | 2.85B | 2.85B | 3.07B |
| Other Current Liabilities | 15.75B | 13.34B | 10.17B |
| Total Current Liabilities | 23.42B | 23.42B | 19.23B |
| Total Liabilities | 78.98B | 78.92B | 79.31B |
| Long Term Debt | 41.85B | 42.56B | 43.53B |
| Current Long Term Debt | 4.82B | 4.25B | 3.26B |
| Minority Interest | 66M | 5M | 9M |
| Common Stock | 44.74B | 2.25B | 2.26B |
| Treasury Stock | -25.65B | 25.65B | 24.76B |
| Retained Earnings | 31.57B | 31.57B | 32.67B |
| Capital Surplus | N.A | 44.44B | 43.25B |
| Shareholder Equity | 49.09B | 49.09B | 49.91B |
| Other Liabilities | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 12.35B | 30.49B | 28.40B | 7.34B |
| Receivables | 6.48B | 4.29B | 4.50B | 4.65B |
| Inventory | 4.29B | 1.19B | 1.31B | 1.28B |
| Current Assets | 29.35B | 40.19B | 37.72B | 17.09B |
| Other Current Assets | 1.23B | 0.95B | 1.38B | 1.29B |
| Short Term Investments | 3.05B | 2.05B | 0.95B | 1.43B |
| Long Term Investments | 4.56B | 1.19B | 1.49B | 1.36B |
| Property/Plant Equipment | 6.96B | 5.33B | 5.36B | 5.51B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 63.97B | 1B | 1B | 1.03B |
| Tangible Assets (Net) | -61.48B | 525M | -1.06B | -1.87B |
| Other Assets | 2.11B | 1.59B | 1.63B | 1.91B |
| Total Assets | 129.94B | 57.43B | 55.16B | 34.83B |
| Accounts Payable | 2.45B | 1.89B | 2.01B | 1.98B |
| Other Current Liabilities | 10.86B | 7.42B | 6.73B | 5.92B |
| Total Current Liabilities | 18.30B | 10.49B | 9.71B | 8.84B |
| Total Liabilities | 78.25B | 39.68B | 39.01B | 19.52B |
| Long Term Debt | 44.06B | 24.89B | 24.95B | 6.16B |
| Current Long Term Debt | 2.76B | N.A | N.A | N.A |
| Minority Interest | -4M | 13M | 7M | 5M |
| Common Stock | 2.23B | 1.63B | 1.64B | 1.64B |
| Treasury Stock | 25.36B | 19.87B | 19.57B | 19.57B |
| Retained Earnings | 34.47B | 36.56B | 35.87B | 35.11B |
| Capital Surplus | 43.71B | 2.21B | 2.15B | 2.10B |
| Shareholder Equity | 51.60B | 17.65B | 16.05B | 15.22B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 6.91B | 5.41B | 5B | 5.34B |
| Receivables | 5.07B | 4.82B | 4.32B | 4.37B |
| Inventory | 1.20B | 1.28B | 1.24B | 1.23B |
| Current Assets | 17.16B | 14.87B | 13.87B | 14.65B |
| Other Current Assets | 1.30B | 693M | 1B | 0.97B |
| Short Term Investments | 1.97B | 1.42B | 1.08B | 1.43B |
| Long Term Investments | 1.89B | 2.32B | 2.40B | 2.50B |
| Property/Plant Equipment | 5.03B | 5.09B | 5.08B | 5.06B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 1.09B | 1.11B | 1.09B | 1.12B |
| Tangible Assets (Net) | -3.1B | -4.11B | -5.36B | -5.22B |
| Other Assets | 1.89B | 2.01B | 2B | 1.53B |
| Total Assets | 34.99B | 33.73B | 32.64B | 33.08B |
| Accounts Payable | 1.89B | 1.77B | 1.87B | 1.73B |
| Other Current Liabilities | 6.66B | 5.95B | 5.92B | 5.68B |
| Total Current Liabilities | 10.65B | 9.69B | 9.88B | 9.62B |
| Total Liabilities | 20.86B | 19.98B | 20.22B | 20.18B |
| Long Term Debt | 5.65B | 5.69B | 5.67B | 5.78B |
| Current Long Term Debt | 1.25B | 1.25B | 1.26B | 1.25B |
| Minority Interest | -2M | 11M | 9M | 9M |
| Common Stock | 1.62B | 1.63B | 1.63B | 1.63B |
| Treasury Stock | 19.57B | 19.58B | 19.58B | 19.43B |
| Retained Earnings | 34.07B | 33.29B | 32.04B | 32.32B |
| Capital Surplus | 2.08B | 2.03B | 1.97B | 1.92B |
| Shareholder Equity | 14.03B | 13.64B | 12.32B | 12.79B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 5.42B | 4.64B | 3.47B |
| Receivables | 4.87B | 5.21B | 5.10B |
| Inventory | 1.17B | 1.25B | 1.22B |
| Current Assets | 14.85B | 15.05B | 14.32B |
| Other Current Assets | 1.27B | 1.09B | 1.14B |
| Short Term Investments | 1.39B | 2.48B | 3.04B |
| Long Term Investments | 2.55B | 2.53B | 2.58B |
| Property/Plant Equipment | 5B | 5.01B | 4.94B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 1.21B | 1.21B | 1.25B |
| Tangible Assets (Net) | -6.32B | -3.24B | -3.3B |
| Other Assets | 1.47B | 0.97B | 883M |
| Total Assets | 33.55B | 33.98B | 33.41B |
| Accounts Payable | 2.25B | 1.70B | 1.55B |
| Other Current Liabilities | 6.10B | 6.07B | 5.87B |
| Total Current Liabilities | 9.56B | 9.44B | 9.02B |
| Total Liabilities | 21.70B | 19.06B | 18.59B |
| Long Term Debt | 6.98B | 6.98B | 6.91B |
| Current Long Term Debt | N.A | N.A | 750M |
| Minority Interest | -1M | 11M | 6M |
| Common Stock | 1.63B | 1.64B | 1.64B |
| Treasury Stock | 19.25B | 19B | 18.78B |
| Retained Earnings | 31.16B | 34.14B | 33.93B |
| Capital Surplus | 1.90B | 1.85B | 1.79B |
| Shareholder Equity | 11.74B | 14.78B | 14.70B |
| Other Liabilities | N.A | N.A | N.A |
Bristol-Myers Squibb Company cash flow (2020) (USD)
| August 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | -85M | -85M | -775M |
| Depreciation | 5.04B | 2.56B | 2.48B |
| Changes in Receivables | -435M | 501M | -724M |
| Changes in Inventories | -452M | 642M | 1.45B |
| Cash Change | 3.34B | 4.12B | 3.43B |
| Cash Flow | 8.16B | 4.27B | 3.89B |
| Capital Expenditures | -317M | -131M | -186M |
| Investments | N.A | 0.92B | 659M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 1.43B | 780M | 653M |
| Dividends Paid | N.A | -1.02B | -1.02B |
| Net Borrowings | 22.57B | -48M | 26M |
| Other Financing Cash Flows | N.A | 76M | 18M |
| Cash Flow Financing | -2.05B | -0.99B | -1.05B |
| Exchange Rate Effect | N.A | 60M | -67M |
Bristol-Myers Squibb Company cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -1.06B | 1.35B | 1.43B | 1.71B |
| Depreciation | 1.24B | 171M | 169M | 170M |
| Changes in Receivables | -2.19B | 214M | 142M | 421M |
| Changes in Inventories | 470M | -35M | -7M | 35M |
| Cash Change | -17.67B | 2.09B | 21.07B | 424M |
| Cash Flow | 2.04B | 2.56B | 2.08B | 1.39B |
| Capital Expenditures | -251M | -190M | -191M | -204M |
| Investments | -0.97B | -1.03B | 743M | 1.11B |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -12.04B | 491M | 715M | 1.06B |
| Dividends Paid | -668M | -671M | -671M | -669M |
| Net Borrowings | 4M | 31M | 18.94B | -1.32B |
| Other Financing Cash Flows | -13M | -1M | -2M | -37M |
| Cash Flow Financing | -7.68B | -0.94B | 18.27B | -2.03B |
| Exchange Rate Effect | 6M | -21M | 3M | 3M |
Bristol-Myers Squibb Company cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | 1.19B | 1.90B | 373M | 1.49B |
| Depreciation | 172M | 165M | 157M | 143M |
| Changes in Receivables | -251M | -492M | 51M | 495M |
| Changes in Inventories | -64M | -30M | -118M | -4M |
| Cash Change | 1.50B | 409M | -343M | -79M |
| Cash Flow | 2.43B | 1.28B | 1.06B | 1.18B |
| Capital Expenditures | -290M | -224M | -198M | -239M |
| Investments | -317M | -242M | 476M | 157M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -336M | -147M | -348M | -43M |
| Dividends Paid | -653M | -653M | -654M | -653M |
| Net Borrowings | 74M | -71M | -207M | -344M |
| Other Financing Cash Flows | 1M | 4M | -1M | -58M |
| Cash Flow Financing | -578M | -720M | -1.02B | -1.22B |
| Exchange Rate Effect | -12M | -3M | -37M | 11M |
Bristol-Myers Squibb Company cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -2.33B | 845M | 0.92B |
| Depreciation | 197M | 188M | 211M |
| Changes in Receivables | 341M | -115M | -115M |
| Changes in Inventories | -36M | 65M | 13M |
| Cash Change | 777M | 1.17B | -440M |
| Cash Flow | 1.12B | 1.71B | 1.58B |
| Capital Expenditures | -254M | -262M | -248M |
| Investments | 1.11B | 620M | -717M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 1.02B | 142M | -1.02B |
| Dividends Paid | -639M | -640M | -643M |
| Net Borrowings | -471M | 148M | -366M |
| Other Financing Cash Flows | 7M | 6M | 3M |
| Cash Flow Financing | -1.35B | -706M | -1.01B |
| Exchange Rate Effect | -7M | 25M | 6M |
Bristol-Myers Squibb Company dividends (USD)
| Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
|---|---|---|---|---|---|---|
| 31-12-2020 | 01-02-2021 | 04-01-2021 | N.A | 0.49 | Ordinary Shares | Quarterly |
| 01-10-2020 | 02-11-2020 | 02-10-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 01-10-2020 | 02-11-2020 | 02-10-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 02-07-2020 | 03-08-2020 | 06-07-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 02-04-2020 | 01-05-2020 | 03-04-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 02-01-2020 | 03-02-2020 | 03-01-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 03-10-2019 | 01-11-2019 | 04-10-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 03-07-2019 | 01-08-2019 | 05-07-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 04-04-2019 | 01-05-2019 | 05-04-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 03-01-2019 | 01-02-2019 | 04-01-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 04-10-2018 | 01-11-2018 | 05-10-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 05-07-2018 | 01-08-2018 | 06-07-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 05-04-2018 | 01-05-2018 | 06-04-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 04-01-2018 | 01-02-2018 | 05-01-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 05-10-2017 | 01-11-2017 | 06-10-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 05-07-2017 | 01-08-2017 | 07-07-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 05-04-2017 | 01-05-2017 | 07-04-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 04-01-2017 | 01-02-2017 | 06-01-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 05-10-2016 | 01-11-2016 | 07-10-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 29-06-2016 | 01-08-2016 | 01-07-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-03-2016 | 02-05-2016 | 01-04-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-12-2015 | 01-02-2016 | 04-01-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-09-2015 | 02-11-2015 | 02-10-2015 | N.A | 0.37 | Ordinary Shares | Quarterly |
| 01-07-2015 | 03-08-2015 | 06-07-2015 | N.A | 0.37 | Ordinary Shares | Quarterly |
Insider Roster
| Entity name | Report date | Shares held |
|---|---|---|
| von Autenried Paul | 30-11-2020 | 126,698 |
| Caforio Giovanni | 02-09-2020 | 445,584 |
| LEUNG SANDRA | 17-08-2020 | 432,744 |
| Hirawat Samit | 02-07-2020 | 28,069 |
Insider Summary
| Full name | Reported title | Total bought | Total sold | Net transacted |
|---|---|---|---|---|
| GROBSTEIN MICHAEL | 8,170 | 0 | 8,170 |
Insider Transactions
| Full name | Reported title | Effective date | Amount of shares | Price per share | Total cost |
|---|---|---|---|---|---|
| AHMED NADIM | EVP and President, Hematology | 02-12-2020 | +6,594 | N.A | N.A |
| BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | 02-12-2020 | +2,637 | N.A | N.A |
| VESSEY RUPERT | EVP, Research & Early Dev. | 02-12-2020 | +8,792 | N.A | N.A |
| Elkins David V | EVP, Chief Financial Officer | 02-12-2020 | +8,792 | N.A | N.A |
| Eid Joseph | SVP,Head Glob. Medical Affairs | 01-12-2020 | +2,825 | N.A | N.A |
| von Autenried Paul | EVP, Chief Information Officer | 25-11-2020 | -3 | 63.50 | 190.50 |
| Dubow Adam | SVP,ChiefCompliance&EthicsOff. | 24-11-2020 | -900 | 63.39 | 57,051.00 |
| von Autenried Paul | EVP, Chief Information Officer | 24-11-2020 | -20,000 | 62.75 | 1,255,000.00 |
| VESSEY RUPERT | EVP, Research & Early Dev. | 23-11-2020 | -13,421 | 61.34 | 823,244.00 |
| VESSEY RUPERT | EVP, Research & Early Dev. | 19-11-2020 | +8,487 | N.A | N.A |
| VESSEY RUPERT | EVP, Research & Early Dev. | 30-10-2020 | +5,804 | N.A | N.A |
| AHMED NADIM | EVP and President, Hematology | 30-10-2020 | +4,650 | N.A | N.A |
| Rice Derica W | N.A | 04-09-2020 | -12 | 72.50 | 870.00 |
| Santiago Karen Murphy | SVP & Controller | 01-09-2020 | -220 | 60.97 | 13,413.40 |
| Caforio Giovanni | Chairman and CEO | 31-08-2020 | -39,840 | 62.70 | 2,497,970.00 |
| Eid Joseph | SVP,Head Glob. Medical Affairs | 17-08-2020 | -5,327 | 64.00 | 340,928.00 |
| LEUNG SANDRA | EVP, General Counsel | 13-08-2020 | -141,420 | 63.24 | 8,943,400.00 |
| Elkins David V | EVP, Chief Financial Officer | 01-08-2020 | -25,916 | 58.66 | 1,520,230.00 |
| Santiago Karen Murphy | SVP & Controller | 01-07-2020 | -367 | 59.43 | 21,810.80 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 01-07-2020 | +9,356 | N.A | N.A |
| Paliwal Dinesh C | N.A | 15-06-2020 | +9,174 | 54.50 | +499,983.00 |
| Haller Julia A | N.A | 14-06-2020 | +558 | N.A | N.A |
| BONNEY MICHAEL W | N.A | 14-06-2020 | +558 | N.A | N.A |
| BONNEY MICHAEL W | N.A | 13-06-2020 | +903 | N.A | N.A |
| Haller Julia A | N.A | 13-06-2020 | +903 | N.A | N.A |
| Haller Julia A | N.A | 03-06-2020 | +2,949 | N.A | N.A |
| Eid Joseph | SVP,Head Glob. Medical Affairs | 03-06-2020 | +2,154 | N.A | N.A |
| BONNEY MICHAEL W | N.A | 03-06-2020 | +2,949 | N.A | N.A |
| Dubow Adam | SVP,ChiefCompliance&EthicsOff. | 22-05-2020 | -3,200 | 61.01 | 195,232.00 |
| Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | 19-05-2020 | -25,000 | 62.68 | 1,567,000.00 |
| AHMED NADIM | EVP and President, Hematology | 01-05-2020 | +2,908 | N.A | N.A |
| VESSEY RUPERT | EVP, Research & Early Dev. | 01-05-2020 | -5,274 | 60.26 | 317,811.00 |
| Mily Elizabeth | EVP, Strategy & BD | 01-04-2020 | +10,738 | N.A | N.A |
| Mily Elizabeth | EVP, Strategy & BD | 01-04-2020 | +14,649 | N.A | N.A |
| Bancroft Charles A | EVP, Head of Integration | 10-03-2020 | +7,324 | N.A | N.A |
| Metcalfe Kathryn | EVP, Corporate Affairs | 10-03-2020 | +8,126 | N.A | N.A |
| Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | 10-03-2020 | -717 | 57.93 | 41,535.80 |
| Santiago Karen Murphy | Controller | 10-03-2020 | +410 | N.A | N.A |
| AHMED NADIM | EVP and President, Hematology | 10-03-2020 | +21,388 | N.A | N.A |
| Caforio Giovanni | Chairman and CEO | 10-03-2020 | -9,038 | 57.93 | 523,571.00 |
| Powell Ann | EVP, Chief Human Resources | 10-03-2020 | -1,496 | 57.93 | 86,663.30 |
| von Autenried Paul | EVP, Chief Information Officer | 10-03-2020 | +2,512 | N.A | N.A |
| BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | 10-03-2020 | -6,157 | 57.43 | 353,596.00 |
| Dubow Adam | SVP,ChiefCompliance&EthicsOff. | 10-03-2020 | +415 | N.A | N.A |
| Eid Joseph | SVP,Head Glob. Medical Affairs | 10-03-2020 | +4,875 | N.A | N.A |
| Elicker John E | EVP, Investor Relations | 10-03-2020 | +1,349 | N.A | N.A |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 10-03-2020 | +25,139 | N.A | N.A |
| Elkins David V | EVP, Chief Financial Officer | 10-03-2020 | +32,102 | N.A | N.A |
| LEUNG SANDRA | EVP, General Counsel | 10-03-2020 | +6,270 | N.A | N.A |
| VESSEY RUPERT | EVP, Research & Early Dev. | 10-03-2020 | +44,541 | N.A | N.A |
| Elicker John E | EVP, Investor Relations | 04-03-2020 | -15,805 | 61.01 | 964,263.00 |
| VESSEY RUPERT | Pres., Research & Early Dev. | 02-03-2020 | +8,489 | 38.41 | +326,062.00 |
| VESSEY RUPERT | Pres., Research & Early Dev. | 01-03-2020 | +23,349 | N.A | N.A |
| Elkins David V | EVP, Chief Financial Officer | 01-03-2020 | +24,579 | N.A | N.A |
| AHMED NADIM | President, Hematology | 01-03-2020 | +17,204 | N.A | N.A |
| VESSEY RUPERT | Pres., Research & Early Dev. | 04-02-2020 | +3,592 | N.A | N.A |
| AHMED NADIM | President, Hematology | 04-02-2020 | +2,076 | N.A | N.A |
| Metcalfe Kathryn | EVP, Corporate Affairs | 03-02-2020 | +13,870 | N.A | N.A |
| Phyllis R. Yale | Director | 31-12-2019 | +178 | N.A | N.A |
| Robert J. Bertolini | Director | 31-12-2019 | +516 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 31-12-2019 | -7,910 | 64.19 | 507,742.90 |
| Karen H. Vousden | Director | 31-12-2019 | +604 | N.A | N.A |
| Matthew W. Emmens | Director | 31-12-2019 | +565 | N.A | N.A |
| David V. Elkins | EVP, Chief Financial Officer | 31-12-2019 | +12,373 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 31-12-2019 | +16,060 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 31-12-2019 | +16,060 | N.A | N.A |
| Julia A. Haller | Director | 31-12-2019 | +178 | N.A | N.A |
| Peter J. Arduini | Director | 31-12-2019 | +565 | N.A | N.A |
| Dinesh C Paliwal | Director | 31-12-2019 | +574 | N.A | N.A |
| Director | 31-12-2019 | +273 | N.A | N.A | |
| Director | 31-12-2019 | +477 | N.A | N.A | |
| Gerald L. Storch | Director | 31-12-2019 | +506 | N.A | N.A |
| Theodore Rapp Samuels | Director | 31-12-2019 | +477 | N.A | N.A |
| Michael W. Bonney | Director | 31-12-2019 | +126 | N.A | N.A |
| David V. Elkins | EVP, Chief Financial Officer | 31-12-2019 | +12,373 | N.A | N.A |
| David V. Elkins | EVP, Chief Financial Officer | 31-12-2019 | -6,094 | 64.19 | 391,173.86 |
| Charles A. Bancroft | EVP, Head of Integration | 11-12-2019 | -3,685 | N.A | N.A |
| Adam Dubow | Chief Compliance & Ethics Offi | 05-12-2019 | -1,740 | 58.81 | 102,329.40 |
| Michael W. Bonney | Director | 04-12-2019 | +88 | 58.90 | +5,183.20 |
| Christopher S. Boerner | EVP, Chief Commercial Officer | 02-12-2019 | +10,550 | N.A | N.A |
| David V. Elkins | EVP, Chief Financial Officer | 02-12-2019 | +35,168 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 02-12-2019 | +35,168 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 02-12-2019 | +26,376 | N.A | N.A |
| SVP,Head Glob. Medical Affairs | 01-12-2019 | +2,825 | N.A | N.A | |
| SVP,Head Glob. Medical Affairs | 01-12-2019 | +2,825 | N.A | N.A | |
| SVP,Head Glob. Medical Affairs | 01-12-2019 | -968 | 56.94 | 55,117.92 | |
| Rupert J. Vessey | Pres., Research & Early Dev. | 20-11-2019 | +4,359 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +33,183 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +14,946 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +51,614 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +6,228 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +9,965 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +4,650 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +2,908 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +19,621 | N.A | N.A |
| Nadim Ahmed | President, Hematology | 20-11-2019 | +19,619 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 20-11-2019 | +24,134 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 20-11-2019 | +18,003 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 20-11-2019 | +5,843 | N.A | N.A |
| Rupert J. Vessey | Pres., Research & Early Dev. | 20-11-2019 | +5,843 | N.A | N.A |